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Nephrotoxicity in Patients with or
without Cystic Fibrosis Treated with
Polymyxin B Compared to Colistin
Ryan L. Crass,a W. Cliff Rutter,a,b Donna R. Burgess,a,b Craig A. Martin,a,b
David S. Burgessb
Department of Pharmacy Services, UK HealthCare, Lexington, Kentucky, USAa; Department of Pharmacy
Practice and Science, University of Kentucky College of Pharmacy, Lexington, Kentucky, USAb
ABSTRACT Nephrotoxicity is the primary adverse effect of the polymyxins. The rela-
tive rates of toxicity of polymyxin B and colistin have not been fully elucidated, es-
pecially in patients with cystic fibrosis (CF). A retrospective cohort study of adults
treated with polymyxin B or colistin for at least 48 h was conducted. The primary
endpoint was the incidence of kidney injury assessed by RIFLE (i.e., risk, injury, fail-
ure, loss, end-stage renal disease) criteria. Risk factors for kidney injury were evalu-
ated using multivariate Cox regression. A total of 414 patients were evaluated, 220
of whom had CF. In patients without CF, there was no difference in kidney injury
with polymyxin B and colistin (42.9% versus 50.3%, P  0.46). Loop diuretic expo-
sure was a risk factor for kidney injury (adjusted hazard ratio [aHR], 1.82; 95% confi-
dence interval [CI], 1.16 to 2.83) in this population. In patients with CF, polymyxin B
and colistin were associated with similar rates of kidney injury (34.5% versus 29.8%,
P  0.77). Diabetes (aHR, 2.68; 95% CI, 1.01 to 7.11), loop diuretics (aHR, 3.02; 95%
CI, 1.36 to 6.73), and progressive care unit admission (aHR, 8.21; 95% CI, 2.55 to
26.46) were risk factors for kidney injury, while higher baseline serum creatinine lev-
els (per 1 mg/dl) were protective (aHR, 0.08; 95% CI, 0.01 to 0.48). Total unadjusted
kidney injury in polymyxin-treated patients was less frequent in those who had CF
(30.5% versus 48.5%, P  0.001). Polymyxin B and colistin are associated with a high
incidence of kidney injury; cystic fibrosis may be protective against polymyxin neph-
rotoxicity, but further investigation is needed to confirm this conjecture.
KEYWORDS clinical therapeutics, multidrug resistance, pharmacokinetics,
pharmacology, toxicity
The increasing prevalence of multidrug-resistant (MDR) Gram-negative bacteriacoupled with the lack of novel agents in the drug development pipeline has left
clinicians with a rapidly dwindling armamentarium of effective antimicrobials (1, 2).
Despite clinical use beginning over half a century ago, the polymyxin class of antibiotics
retains activity against many MDR pathogens—namely, carbapenem-resistant Entero-
bacteriaceae (CRE), Pseudomonas aeruginosa, and Acinetobacter baumannii (3).
There are two systemically available agents in the polymyxin class: colistin (poly-
myxin E) and polymyxin B (PMB). While the pharmacologically active moieties are
structurally similar, colistin is administered intravenously as a prodrug—colistimethate
sodium (CMS) (3). Recent pharmacokinetic data suggest that conversion from colisti-
methate to pharmacologically active colistin exhibits high interpatient variability and is
affected by the proportion of prodrug lost to renal elimination prior to activation (4–7).
Polymyxin B, on the other hand, is administered directly as an active drug and
undergoes only minimal renal elimination. These properties provide a compelling
pharmacokinetic rationale for the use of PMB over CMS in the absence of differential
toxicity (8).
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For the antimicrobials which fell out of favor largely due to high rates of kidney
injury, the issue of the relative levels of toxicity of the two agents has been investigated
only recently. Historical rates of nephrotoxicity are confounded by variable and insen-
sitive definitions of acute kidney injury (AKI) as well as by inadequate dosing by current
standards. Recent toxicity studies suggested a higher incidence of nephrotoxicity with
CMS than with PMB; however, this has not been consistently demonstrated (9–12).
The effect of underlying diseases which may alter the pharmacokinetic properties of
the polymyxins has also been poorly investigated. Patients with cystic fibrosis (CF) have
a high burden of MDR Gram-negative infections and may require treatment with
polymyxins, and yet there are a paucity of pharmacokinetic and toxicity data in this
patient population (13, 14). Phe and colleagues found CF to be a factor that is
protective against the development of nephrotoxicity with CMS but were precluded
from conducting a similar analysis with PMB due to a lack of baseline CF in the PMB
cohort (12). Additionally, to our knowledge the relative rates of toxicity of the two
systemic polymyxins have not been investigated in this patient population. We hy-
pothesized that CMS would be more nephrotoxic than PMB in patients without cystic
fibrosis and that this relationship would be reversed in patients with CF owing to
differences in drug elimination. The objective of this study was to determine the
incidence of acute kidney injury in patients with and without cystic fibrosis treated with
colistin or polymyxin B.
RESULTS
Non-cystic fibrosis patients. (i) Patient characteristics. In total, 194 patients were
included in the non-cystic fibrosis cohort (Fig. 1), 49 (25.3%) of whom received PMB and
145 (74.7%) of whom received CMS. Patients treated with PMB were older (57 [inter-
quartile range {IQR}, 50 to 67] versus 51 [IQR, 37 to 62] years of age, P  0.006) and
more likely to be Caucasian (98.0% versus 84.1%, P  0.02) than those treated with
CMS. The median baseline serum creatinine levels were 1.3 mg/dl (IQR, 0.7 to 2.3 mg/dl)
and 1.1 mg/dl (IQR, 0.7 to 2.0 mg/dl; P 0.33) in the PMB and CMS groups, respectively.
Additional baseline characteristics are summarized in Table 1.
FIG 1 Enrollment and exclusion. Abbreviations: AKI, acute kidney injury; PMB, polymyxin B; CMS,
colistimethate sodium.
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(ii) Characteristics of polymyxin therapy. Characteristics of therapy with PMB and
CMS are summarized in Table 2. Patients were much more likely to receive a loading
dose with PMB than with CMS (73.5% versus 13.8%, P  0.001). Concurrent antibiotic
exposure was seen in all patients in both treatment arms. The median durations of
TABLE 1 Baseline characteristics of all patientsa
Parameter
Value(s)
Non-cystic fibrosis patients Cystic fibrosis patients
PMB
(n  49)
CMS
(n  145) P
PMB
(n  29)
CMS
(n  191) P
Demographics
Age (yrs) 57 (50–67) 51 (37–62) 0.006 27 (22–31) 23 (20–30) 0.03
Male sex 31 (63.3%) 92 (63.5%) 1.00 13 (44.8%) 82 (42.9%) 1.00
Caucasian 48 (98.0%) 122 (84.1%) 0.02 29 (100.0%) 191 (100.0%)
CCI 5 (3–7) 5 (3–8) 0.70 4 (2–6) 4 (3–5) 0.61
Hypertension 33 (67.4%) 93 (64.1%) 0.82 15 (51.7%) 73 (38.2%) 0.24
Diabetes 27 (55.1%) 68 (46.9%) 0.41 20 (69.0%) 152 (79.6%) 0.29
ABW (kg) 83.0 (74.8–99.3) 80.3 (64.2–99.6) 0.25 55.0 (50.7–59.0) 51.3 (45.3–56.2) 0.02
IBW (kg) 66.1 (57.0–75.3) 68.4 (54.7–75.3) 0.73 59.3 (50.1–70.7) 57.0 (49.5–66.1) 0.32
Site of care
ICU 19 (38.8%) 44 (30.3%) 3 (10.3%) 8 (4.2%)
PCU 10 (20.4%) 51 (35.2%) 0.15 2 (6.9%) 14 (7.3%) 0.33
Acute 20 (40.8%) 50 (34.5%) 24 (82.8%) 169 (88.5%)
Clinical baseline
Scr (mg/dl) 1.3 (0.7–2.3) 1.1 (0.7–2.0) 0.33 0.8 (0.6–0.9) 0.7 (0.6–0.8) 0.01
CrCL (ml/min)b 63 (27–100) 74 (37–125) 0.16 135 (114–158) 158 (128–188) 0.01
Serum albumin (mg/dl) 2.1 (1.7–2.6) 2.3 (1.7–2.8) 0.27 2.8 (2.4–3.1) 2.9 (2.6–3.2) 0.34
Mechanical ventilation 22 (44.9%) 82 (56.6%) 0.19 2 (6.9%) 1 (0.5%) 0.046
Concurrent nephrotoxinsc
Aminoglycosides 12 (24.5%) 50 (34.5%) 0.26 12 (41.4%) 34 (17.8%) 0.008
Amphotericin B 1 (2.0%) 8 (5.5%) 0.45
Vancomycin 24 (49.0%) 96 (66.2%) 0.048 10 (34.5%) 50 (26.2%) 0.48
Calcineurin inhibitors 3 (6.1%) 15 (10.3%) 0.57 9 (31.0%) 13 (6.8%) 0.001
Intravenous contrast 4 (8.2%) 3 (2.1%) 0.07 1 (3.5%) 2 (1.1%) 0.35
Loop diuretics 21 (42.9%) 70 (48.3%) 0.62 7 (24.1%) 19 (10.0%) 0.06
NSAIDS 1 (2.04%) 18 (12.4%) 0.048 3 (10.3%) 22 (11.5%) 1.00
Vasopressors 11 (22.5%) 41 (28.3%) 0.54 3 (10.3%) 0 (0%) 0.002
aAbbreviations: PMB, polymyxin B; CMS, colistimethate sodium; CCI, Charlson comorbidity index; ABW, actual body weight; IBW, ideal body weight; ICU, intensive care
unit; PCU, progressive care unit; Scr, serum creatinine; CrCL, creatinine clearance; NSIADs, nonsteroidal anti-inflammatory drugs. Values (other than P values) are
presented as mean ( standard deviation [SD]), n (%), or median (IQR).
bData were calculated using the modified Cockroft-Gault equation: CrCL  [(140  age in years)/(Scr value)] ( 0.85 for female subjects).
cConcurrent use is defined as administration within 24 h prior to the first polymyxin dose through the end of polymyxin therapy.
TABLE 2 Characteristics of polymyxin therapy in all patientsa
Parameter
Value(s)
Non-cystic fibrosis patients Cystic fibrosis patients
PMB
(n  49)
CMS
(n  145) P
PMB
(n  29)
CMS
(n  191) P
Loading dose used 36 (73.5%) 20 (13.8%) 0.001 11 (37.9%) 4 (2.1%) 0.0001
Loading dose (mg/kg)bc 1.9 (0.5) 3.5 (1.0) 1.6 (0.3) 2.9 (1.5)
Total daily dose (mg/day)bc 200.9 (81.3) 226.4 (106.1) 124.4 (34.2) 213.5 (67.5)
Total daily dose (mg/kg/day)bc 2.3 (0.7) 3.4 (1.6) 2.2 (0.4) 4.1 (1.1)
Duration of therapy (days) 5 (4–10) 7 (3–13) 0.44 8 (5–21) 8 (6–13) 0.53
Concurrent antibioticsd 49 (100.0%) 145 (100.0%) 29 (100%) 191 (100%)
aAbbreviations: PMB, polymyxin B; CMS, colistimethate sodium. Values (other than P values) are presented as mean ( SD), n (%), or median (IQR).
bDosing data per unit body weight was calculated using actual body weight (ABW) for PMB and ideal body weight (IBW) for CMS. ABW was used for CMS if ABW was
less than IBW.
cCMS doses are expressed as milligrams of colistin base activity (CBA).
dConcurrent use is defined as administration within 24 h prior to the first polymyxin dose through the end of polymyxin therapy.
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polymyxin therapy were 5 days (IQR, 4 to 10) with PMB and 7 days (IQR, 3 to 13) with
CMS (P  0.44).
(iii) Outcomes. Acute kidney injury occurred in 21/49 (42.9%) of patients treated
with PMB compared to 73/145 (50.3%) treated with CMS (P  0.46; Fig. 2). There were
no statistically significant differences between groups for each individual RIFLE stage.
The median time to peak serum creatinine was 3 days (IQR, 2 to 6 days) with PMB
compared to 6 days (IQR, 3 to 10 days) with CMS (P  0.03), with no difference in the
maximum serum creatinine values obtained (Table 3). Renal recovery occurred in 13/21
FIG 2 Acute kidney injury by RIFLE stage in non-cystic fibrosis patients treated with polymyxin B versus
colistin. P values were nonsignificant (0.05) for all comparisons. Relative number of patients per
outcome stratum: Total, PMB  21/49, CMS  73/145; Risk, PMB  14/49, CMS  34/145; Injury, PMB 
6/49, CMS  33/145; Failure, PMB  1/49, CMS  6/145.
TABLE 3 Outcomes in all patientsa
Parameter
Value(s)
Non-cystic fibrosis patients Cystic fibrosis patients
PMB
(n  49)
CMS
(n  145) P
PMB
(n  29)
CMS
(n  191) P
Primary outcome
Acute kidney injury 21 (42.9%) 73 (50.3%) 0.46 10 (34.5%) 57 (29.8%) 0.77
Secondary outcomes
Toxicity
RIFLE stageb
Risk 14 (28.6%) 34 (23.5%) 0.60 7 (24.1%) 50 (26.2%) 1.00
Injury 6 (12.2%) 33 (22.8%) 0.17 3 (10.3%) 7 (3.7%) 0.13
Failure 1 (2.0%) 6 (4.1%) 0.68 0 (0%) 0 (0%)
Time course
Time to peak
Scr (days)
3 (2–6) 6 (3–10) 0.03 5 (4–15) 5 (4–9) 0.56
Peak Scr (mg/dl) 1.5 (0.9–3.1) 1.7 (0.9–3.2) 0.96 1.0 (0.7–1.7) 0.7 (0.6–0.9) 0.002
Renal recoveryc 13 (61.9%) 45 (61.6%) 1.00 9 (90.0%) 52 (91.2%) 1.00
Efficacy
In-hospital
mortality
3 (6.1%) 18 (12.4%) 0.34 1 (3.5%) 1 (0.5%) 0.25
30-day mortality 6 (12.2%) 27 (18.6%) 0.42 1 (3.5%) 2 (1.1%) 0.35
LOS (days) 24 (12–35) 23 (12–51) 0.65 14 (7–28) 9 (6–14) 0.008
aAbbreviations: PMB, polymyxin B; CMS, colistimethate sodium; RIFLE, risk, injury, failure, loss, end-stage renal
disease; Scr, serum creatinine; LOS, length of stay. Values (other than P values) are presented as mean
(SD), n (%), or median (IQR).
bThe stages of the RIFLE criteria are defined as follows: risk (25% decrease in CrCL), injury (50% decrease
in CrCL), and failure (75% decrease in CrCL).
cRenal recovery was assessed as return to baseline CrCL strata (i.e., 80 ml/min, 50 to 79 ml/min, 30 to 49
ml/min, and 10 to 29 ml/min).
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(61.9%) of polymyxin B-treated patients and 45/145 (61.6%) of colistin-treated patients
by hospital discharge (P  1.00).
There were no statistically significant differences between PMB and CMS in any of
the secondary efficacy endpoints (Table 3).
(iv) Risk factors. In bivariate analysis, factors associated with the development of AKI
at a P value of0.2 were high polymyxin dose, loading dose, aminoglycosides, intravenous
contrast, loop diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs). In the multi-
variate Cox proportional hazard model, concurrent loop diuretic exposure (adjusted
hazard ratio [aHR], 1.82 [95% confidence interval {CI}, 1.16 to 2.83]) remained indepen-
dently predictive of AKI. The choice of polymyxin (PMB versus CMS) was not predictive
of AKI (Table 4).
Cystic fibrosis patients. (i) Patient characteristics. Of the 220 patients included in
the CF cohort (Fig. 1), 29 (13.2%) were treated with PMB and 191 (86.8%) with CMS. The
TABLE 4 Risk factors for the development of acute kidney injury in non-cystic fibrosis patients treated with polymyxin B or colistin:
bivariate and multivariate analysesa
Variable
Value(s)
Bivariate analysis Multivariate analysis
HR 95% CI P aHR 95% CI P
Polymyxin formulation
Colistin Reference value Reference value
Polymyxin B 0.74 0.42–1.31 0.31 1.07 0.56–2.50 0.83
Characteristics of polymyxin therapy
High doseb 2.11 1.34–3.33 0.001 1.26 0.80–1.97 0.31
Loading dose 0.67 0.39–1.17 0.16 0.78 0.42–1.46 0.44
Duration  10 days 1.38 0.85–2.24 0.20
Demographics
Age  60 yrs 1.30 0.80–2.09 0.29 1.43 0.91–2.52 0.12
CCI 1.00 0.94–1.07 0.97
Caucasian 1.38 0.72–2.68 0.33
Hypertension 0.80 0.50–1.28 0.35
Diabetes 1.11 0.70–1.74 0.66
Site of care
Acute Reference value
ICU 1.11 0.63–1.94 0.72
PCU 0.56 0.20–1.53 0.26
Concurrent nephrotoxinsc
Aminoglycosides 1.50 0.94–2.37 0.09 1.22 0.80–1.87 0.35
Amphotericin B 1.05 0.38–2.90 0.92
Vancomycin 0.82 0.51–1.30 0.40 0.72 0.45–1.13 0.15
Calcineurin inhibitors 0.89 0.40–1.95 0.76
Intravenous contrast 0.27 0.04–1.97 0.20 0.25 0.03–1.86 0.18
Loop diuretics 2.25 1.39–3.65 0.001 1.81 1.16–2.83 0.008
NSAIDS 1.60 0.82–3.12 0.17 1.50 0.78–2.90 0.23
Vasopressors 1.35 0.842.18 0.22
Laboratory abnormalities
Baseline Scr  1.5 1.08 0.66–1.74 0.77
Albumin
3 g/dl Reference value
3 g/dl 0.74 0.43–1.28 0.28
No albumin level 0.85 0.29–2.54 0.77
Total bilirubin
3 mg/dl Reference value
3 mg/dl 0.84 0.36–1.96 0.69
No total bilirubin level 1.10 0.47–2.54 0.83
aAbbreviations: PMB, polymyxin B; CMS, colistimethate sodium; OR, odds ratio; CI, confidence interval; aOR, adjusted odds ratio; CCI, Charlson comorbidity index; ICU,
intensive care unit; PCU, progressive care unit; NSAIDS, nonsteroidal anti-inflammatory drugs; Scr, serum creatinine. The multivariate Cox proportional hazard model
included all variables meeting a significance level of a P value of 0.20 in bivariate analysis or that were significantly different between the PMB and CMS cohorts at
baseline. Data for polymyxin B relative to CMS were forced into the model. Independent predictors of kidney injury are highlighted in bold.
bHigh polymyxin doses are defined as PMB doses of 200 mg/day and CMS doses of 270 mg colistin base activity/day.
cConcurrent use is defined as administration within 24 h prior to the first polymyxin dose through the end of polymyxin therapy.
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patients treated with PMB had a higher median actual body weight (ABW) (55.0 kg [IQR,
50.7 to 59.0 kg]) than the patients treated with CMS (51.3 kg [IQR, 45.3 to 56.2 kg]) (P 
0.02) despite similar median ideal body weights (Table 1). Median baseline serum
creatinine levels were 0.8 mg/dl (IQR, 0.6 to 0.9 mg/dl) with PMB and 0.7 mg/dl (IQR, 0.6
to 0.8 mg/dl; P 0.01) with CMS, corresponding to baseline creatinine clearance (CrCL)
levels of 135 ml/min (IQR, 114 to 158 ml/min) and 158 ml/min (IQR, 128 to 188 ml/min;
P  0.01), respectively.
(ii) Characteristics of polymyxin therapy. Table 2 summarizes factors associated
with polymyxin therapy in patients with CF. As in the non-cystic fibrosis cohort, loading
doses were more commonly employed with PMB (37.9%) than with CMS (2.1%; P 
0.001). The median duration of therapy was 8 days in both groups (P  0.53), and
concurrent antibiotics were used in all patients.
(iii) Outcomes. For the primary outcome, 10/29 (34.5%) of patients treated with
PMB and 57/191 (29.8%) of patients treated with CMS developed AKI (P  0.77; Fig. 3).
Polymyxin B and CMS had statistically similar rates of patients meeting the risk (24.1%
versus 26.2%; P 1.00) and injury (10.3% versus 3.7%; P 0.13) categories of RIFLE. No
patient in either arm met the criteria for failure (75% decrease in CrCL from baseline).
The median peak serum creatinine level was significantly higher with PMB (1.0 mg/dl;
IQR, 0.7 to 1.7 mg/dl) than with CMS (0.7 mg/dl; IQR, 0.6 to 0.9 mg/dl; P  0.002). The
majority of patients, 90.0% with PMB and 91.2% with CMS, had recovered to their
baseline CrCL strata by hospital discharge (P  1.00).
There were no statistically significant differences between PMB and CMS for in-
hospital mortality (3.5% versus 0.5%, P  0.25) or 30-day mortality (3.5% versus 1.1%,
P  0.35). The median hospital length of stay, however, was longer with PMB (14 days;
IQR, 7 to 28 days) than with CMS (9 days; IQR, 6 to 14 days; P  0.008) (Table 3).
(iv) Risk factors. Risk factors associated with the development of AKI in bivariate
analysis (P 0.2) were Charlson comorbidity index (CCI), diabetes, progressive care unit
(PCU) admission, duration of therapy, vancomycin, loop diuretics, NSAIDs, and baseline
albumin. The multivariate Cox proportional hazard model found diabetes (aHR, 2.68
[95% CI, 1.01 to 7.11]), PCU admission (aHR, 8.21 [95% CI, 2.55 to 26.46]), and concurrent
loop diuretics (aHR, 3.02 [95% CI, 1.36 to 6.73]) to be independent predictors of kidney
injury, while elevated baseline serum creatinine levels (per 1 mg/dl) were found to be
protective (aHR, 0.08 [95% CI, 0.01 to 0.48]). Consistent with the non-cystic fibrosis
cohort results, the polymyxin used (PMB versus CMS) was not predictive of AKI.
Complete model results are presented in Table 5.
FIG 3 Acute kidney injury by RIFLE stage in cystic fibrosis patients treated with polymyxin B versus
colistin. P values were nonsignificant (0.05) for all comparisons. Relative number of patients per
outcome stratum: Total, PMB  10/29, CMS  57/191; Risk, PMB  7/29, CMS  50/191; Injury, PMB 
3/29, CMS  7/191; Failure, PMB  0/29, CMS  0/191.
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DISCUSSION
The rates of AKI did not differ between polymyxin B and colistin in patients with
(34.5% versus 29.8%, P 0.77) or without (42.9% versus 50.3%, P 0.46) cystic fibrosis.
Although there was no difference between PMB and CMS in rates of toxicity, it is
notable that AKI developed in a significant proportion of patients treated with either
polymyxin.
Our results are in conflict with recent studies showing higher rates of nephrotoxicity
with CMS than with PMB (10, 12, 15). One explanation for this may be that the
differences in the rates were due to institutional differences in polymyxin dosing.
Patients in the non-cystic fibrosis cohort received a mean daily dose of 2.3 mg/kg of
body weight/day (200.9 mg/day) of polymyxin B by actual body weight, which is
TABLE 5 Risk factors for the development of acute kidney injury in cystic fibrosis patients treated with polymyxin B or colistin: bivariate
and multivariate analysesa
Variable
Value(s)
Bivariate analysis Multivariate analysis
HR 95% CI P aHR 95% CI P
Polymyxin formulation
Colistin Reference value Reference value
Polymyxin B 1.08 0.54–2.15 0.82 1.94 0.78–4.84 0.15
Characteristics of polymyxin therapy
High doseb 0.74 0.38–1.41 0.35
Loading dose 1.04 0.42–2.59 0.94 0.59 0.20–1.77 0.35
Duration  10 days 1.43 0.87–2.34 0.16 1.13 0.63–2.02 0.69
Demographics
Age (per additional yr) 1.02 0.99–1.04 0.21
CCI 1.15 1.05–1.27 0.004 0.97 0.83–1.15 0.76
Hypertension 1.29 0.80–2.09 0.30
Diabetes 2.18 1.04–4.56 0.04 2.68 1.01–7.11 0.049
Wt (per additional kg) 1.00 0.98–1.03 0.82 1.00 0.98–1.03 0.82
Site of care
Acute Reference value Reference value
ICU 1.27 0.60–2.68 0.53 0.78 0.33–1.81 0.56
PCU 3.45 1.38–8.63 0.008 8.21 2.55–26.46 <0.001
Concurrent nephrotoxinsc
Aminoglycosides 1.19 0.68–2.10 0.54
Amphotericin B
Vancomycin 1.67 1.02–2.75 0.04 1.80 0.96–3.35 0.07
Calcineurin inhibitors 0.95 0.43–2.10 0.90 0.84 0.29–2.45 0.75
Intravenous contrast 1.89 0.43–2.10 0.38
Loop diuretics 2.38 1.32–4.27 0.004 3.02 1.36–6.73 0.006
NSAIDS 1.61 0.84–3.08 0.15 1.57 0.70–3.50 0.27
Vasopressors 1.19 0.26–5.45 0.82 0.31 0.04–2.20 0.24
Laboratory abnormalities
Baseline Scr (per additional 1 mg/dl)d 0.08 0.01–0.48 0.006
Albumin
3 g/dl Reference value Reference value
3 g/dl 1.42 0.84–2.38 0.19 1.05 0.56–1.99 0.87
No albumin level 0.72 0.28–1.91 0.51 0.49 0.17–1.42 0.19
Total bilirubin
Total bilirubin  3 mg/dle
aAbbreviations: PMB, polymyxin B; CMS, colistimethate sodium; OR, odds ratio; CI, confidence interval; CCI, Charlson comorbidity index; kg, kilogram; ICU, intensive
care unit; PCU, progressive care unit; NSAIDS, nonsteroidal anti-inflammatory drugs; Scr, serum creatinine. The multivariate Cox proportional hazard model included
all variables meeting a significance level of a P value of 0.20 in bivariate analysis or that were significantly different between the PMB and CMS cohorts at baseline.
Data for polymyxin B relative to CMS were forced into the model. Independent predictors of kidney injury are highlighted in bold.
bHigh polymyxin doses are defined as PMB doses of 200 mg/day and CMS doses of 270 mg colistin base activity/day.
cConcurrent use is defined as administration within 24 h prior to the first polymyxin dose through the end of polymyxin therapy.
dNo patient with cystic fibrosis had a baseline serum creatinine value greater than 1.5; therefore, baseline Scr (per 1 mg/dl increase) was included in the model
due a significant baseline difference between PMB and CMS.
eNo patient with cystic fibrosis had a total bilirubin level of 3 mg/dl.
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concordant with a contemporary study of polymyxin B pharmacokinetics as well as with
the doses used in comparator toxicity studies (1.7 to 2.4 mg/kg/day) (8, 10, 12, 15). In
contrast, patients treated with CMS in our investigation received an average of 3.4 mg
colistin base activity (CBA)/kg/day (226.4 mg CBA/day) by ideal body weight compared
to 3.9 to 4.6 mg CBA/kg/day (275 to 300 mg CBA/day) in previous investigations. The
colistin dosing used in our study is in line with current United States Food and Drug
Administration (FDA) recommendations for patient baseline renal creatinine clearance
of 50 to 80 ml/min (2.5 to 3.8 mg/kg/day) but falls short of the dosing recommended
by the European Medicines Association (EMA) and supported by pharmacokinetic data
(4–6, 16). A recent study by Nation and colleagues found FDA-labeled dosing to be
inferior to the EMA-labeled dosing in attaining target colistin serum levels (16). In
recent years, our institutional practice has shifted to PMB as the preferred agent; thus,
much of the CMS dosing reflects historical practice prior to the publication of recent
pharmacokinetic studies and dosing recommendations. This temporal effect of poly-
myxin use may have biased the results toward lesser toxicity with CMS due to
suboptimal dosing by current standards. Similarly, loading doses have become the
standard of care for polymyxin dosing at our institution only recently and the lower
frequency of loading doses seen with CMS than with PMB may be reflective of historical
practice.
The existing body of evidence suggests that either CMS has greater nephrotoxicity
than PMB or there is no difference in the toxicity levels of these agents (9–12, 15). There
are, however, clear pharmacokinetic advantages to PMB—namely, less interpatient
variability and the lack of a significant renal component to drug elimination (4–8). In the
absence of greater toxicity with PMB than with CMS, we assert that the pharmacoki-
netic argument is sufficient to recommend PMB as the first-line polymyxin for extrau-
rinary infections due to MDR Gram-negative pathogens. Furthermore, it is unlikely that
additional research into comparative nephrotoxicity will yield results that are greatly
contradictory to the existing body of evidence. Therefore, resources should be focused
on novel strategies to mitigate polymyxin toxicity (nephroprotective agents, synergistic
dose sparing, etc.) or to minimize the use of polymyxins altogether (i.e., aminoglycoside
use, novel combination therapy, drug development, etc.) (17–19). In this investigation,
nephrotoxicity was reversible in only about 60% of non-cystic fibrosis patients by
hospital discharge, highlighting the significant effect of this toxicity on patient out-
comes.
The sum of the polymyxin pharmacokinetic and toxicity data in patients with CF is
much less conclusive than in the general population. In our study, there were no
statistically significant differences in the overall rates of AKI with PMB versus CMS
(34.5% versus 29.8%, P  0.77) or in the proportion of patients with recovery of renal
function by hospital discharge (90.0% versus 91.2%, P  1.00) in the CF cohort.
Interestingly, the unadjusted rate of kidney injury in CF patients treated with polymyx-
ins was 30.5% compared to 48.4% in those without the disease (P  0.001). Unfortu-
nately, the significant bias toward the use of CMS for patients with CF precludes the use
of Cox regression to elucidate whether the disease itself is nephroprotective or if
baseline differences in the patient populations are influencing the observed results.
In a study by Phe and colleagues, CF was found to be independently protective
against the development of AKI with CMS in multivariate logistic regression analysis
(odds ratio [OR], 0.03; 95% CI, 0.001 to 0.79; P  0.04) (12). Unfortunately, a parallel
analysis in patients treated with PMB was precluded by the complete lack of CF patients
in the PMB therapy arm. Given that CMS undergoes significant renal elimination, a
potential mechanism of this effect could be that of enhanced elimination of the
prodrug before activation to the more toxic parent molecule in patients with an
augmented renal baseline. A pharmacokinetic study of CMS in CF patients found mean
steady-state terminal half-lives of 2.1 and 4.2 h for colistimethate and colistin, respec-
tively, relative to 4.6 and 9.1 h in patients without CF in a study by Garonzik and
colleagues (4, 14). This theory of reduced toxicity by augmented clearance is concern-
ing because reduced toxicity may then be a marker of reduced efficacy due to an
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increase in the fraction of the colistimethate dose eliminated and a corresponding
decrease in the fraction hydrolyzed to active colistin.
Multivariate Cox proportional hazard analysis identified differing predictors of AKI in
patients with and without cystic fibrosis treated with polymyxins. Notably, loop diuretic
exposure was an independent risk factor for AKI in both cohorts and was the only
exposure significantly associated with AKI in patients without cystic fibrosis. In the CF
cohort, diabetes and progressive care unit admission were independently associated
with AKI whereas a higher baseline serum creatinine level was protective. The associ-
ation between higher serum creatinine values and decreased risk for AKI in patients
with CF may be due to inadequate dosing of colistin or polymyxin B in patients with
renal dysfunction (20). It is notable that the use of loading doses, which are integral to
the rapid attainment of bactericidal drug levels, did not appear to impact toxicity (5, 6,
8, 21).
There are several limitations which must be acknowledged. First, this was a retro-
spective evaluation and therefore subject to selection and chronology biases. All study
outcomes were chosen as objective measures to limit any bias from misinterpretation
of retrospective data; however, polymyxin use was not evenly distributed across the
study period. Colistin-treated patients were enrolled earlier on average than PMB-
treated patients, which likely accounts for the differences in dosing intensity and
loading dose prescribing seen in this investigation. Additionally, there was dispropor-
tionate use of colistin and polymyxin B, with significantly fewer patients receiving PMB
in both cohorts. This may have decreased the statistical power of the Cox models. There
is also the potential for confounding factors contributing to AKI that were not quan-
tified in our analysis. We controlled for multiple factors in the Cox proportional hazard
model, including severity of illness, site of care, comorbidities, renal baseline, and
concurrent nephrotoxins, in order to minimize confounding. Finally, we did not assess
clinical outcomes of polymyxin therapy for treating infection or attempt to correlate
serum drug levels with the development of toxicity.
Conclusions. There was no difference between polymyxin B and colistin in the
incidence of AKI in patients with and without CF; however, the overall rate of kidney
injury was significantly lower in patients with CF. In both cohorts, loop diuretic use was
independently associated with AKI. Diabetes and progressive care unit admission were
associated with increased risk of AKI in patients with CF, while elevated baseline serum
creatinine was protective against AKI in this patient population. Further investigation is
warranted to determine if cystic fibrosis provides differential nephroprotective effects
between colistin and polymyxin B and to confirm whether the effects, if any, exist
independently of cofounding baseline differences in patient populations. Alternative
therapeutic options and novel strategies to mitigate polymyxin nephrotoxicity are
desperately needed.
MATERIALS AND METHODS
Design. This was a retrospective cohort study conducted at the University of Kentucky Albert B.
Chandler and Good Samaritan Hospitals between 1 July 2006 and 30 September 2015. Patients were
enrolled retrospectively from the University of Kentucky Center for Clinical and Translational Science
Enterprise Data Trust database. Institutional review board (IRB) approval was obtained from the Univer-
sity of Kentucky.
Adult patients (18 years old) who received treatment with intravenous PMB or CMS for at least 48
h were eligible for inclusion and were stratified by baseline CF status into two cohorts. Patients receiving
renal replacement therapy at baseline were excluded. Patients who had received either systemic CMS or
PMB within the previous 14 days or those who had been switched from one agent to the other within
a single course of therapy were also excluded. Additionally, we excluded patients with reported height
and/or weight data points greater than four standard deviations from the mean. Polymyxin agent
selection and dosing were at the discretion of the primary care team at the time of therapy, and no
protocols or guidelines were available at either institution during the study period.
Study outcomes. Data collected included demographics (i.e., age, race, sex), admission and dis-
charge dates, site of care, comorbidities, Charlson comorbidity index (CCI), laboratory markers (i.e., serum
creatinine, blood urea nitrogen, albumin, etc.), polymyxin information (i.e., loading dose used, total daily
dose, duration), concomitant anti-infectives, and concomitant nephrotoxins (i.e., aminoglycosides, loop
diuretics, vasopressors, contrast dye, etc.).
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The primary endpoint was the overall incidence of AKI, defined using the RIFLE (risk, injury, failure,
loss, end stage) criteria, in patients treated with systemic PMB or CMS (22). This endpoint was met if
creatinine clearance (CrCL) decreased by 25% or greater from baseline at any time between treatment
initiation and 48 h after the end of polymyxin therapy. Creatinine clearance was determined using the
modified Cockroft-Gault equation (23). Multiple variables were evaluated as risk factors for AKI, including
age, CCI, admission to an intensive care unit (ICU) or progressive care unit (PCU), polymyxin agent used
(PMB versus CMS), loading dose, high polymyxin dose (CMS, 270 mg/day colistin base activity [CBA];
PMB, 200 mg/day), duration of therapy (10 days), concurrent nephrotoxins (aminoglycosides, am-
photericin B, vancomycin, calcineurin inhibitors, intravenous contrast, loop diuretics, nonsteroidal anti-
inflammatory drugs [NSAIDs], vasopressors), elevated baseline serum creatinine (1.5 mg/dl), elevated
total bilirubin (3 mg/dl), and hypoalbuminemia (3 g/dl) (10, 11).
Multiple secondary toxicity and efficacy endpoints were investigated. Secondary toxicity outcomes
included the proportion of patients meeting each stage of the RIFLE criteria, peak serum creatinine, and
the proportion of patients with return to renal baseline. Return to renal baseline was assessed as the
proportion of patients returning to their baseline CrCL strata (i.e., 80 ml/min, 50 to 70 ml/min, 30 to 49
ml/min, 10 to 29 ml/min) by hospital discharge. Secondary efficacy endpoints included in-hospital
mortality, 30-day mortality, and length of stay.
Statistics. Descriptive statistics were calculated as follows. Categorical variables were analyzed using
the chi-square test or Fisher’s exact test as appropriate. Continuous variables were compared using the
Student t test for normally distributed data and the Mann-Whitney U test for non-normally distributed
data. Normality was assessed using the Shapiro-Wilk test. Risk factors for the development of AKI were
assessed using bivariate Cox regression to generate hazard ratios (HR) and 95% confidence intervals (CI).
Variables with a P value of 0.2 in bivariate analysis and those which differed between CMS and PMB
at baseline were included in the final Cox proportional hazard model. The polymyxin antimicrobial used
(PMB versus CMS) was forced into the final model regardless of bivariate association, as the toxicity
difference between these agents was the primary outcome of interest. A power calculation was not
performed due to the retrospective nature of this investigation. All statistical tests were performed in R
(version 3.1.2) and were two-tailed at a significance level of 0.05.
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